Pediatrics might finally have a long-awaited RSV shot
2023 is shaping up to be the year of RSV—in a good way. RSV (a.k.a. respiratory syncytial virus) has long been a challenge for …
Pediatrics might finally have a long-awaited RSV shot Read More »
2023 is shaping up to be the year of RSV—in a good way. RSV (a.k.a. respiratory syncytial virus) has long been a challenge for …
Pediatrics might finally have a long-awaited RSV shot Read More »
Already, 2023 is looking like a dynamic year for biotech on the state level as state legislatures nationwide get ready to tackle a few …
4 things for biotech to watch in the 2023 state legislatures Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed …
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s …
China-U.S. biotech ventures are where collaboration meets competition Read More »
“It’s exciting times,” said Kathy Fernando, Senior Vice President and Global Head of the Partner of Choice Organization at Pfizer Inc. Speaking about the …
Pfizer Ignite’s new model is turning heads and sharing the wealth Read More »
From the colorful glass and plastic bottles that populate medicine cabinets to the ingredients used in common and high-end products, the beauty industry’s output …
Biotech can clean up your beauty cabinet for the new year Read More »
At 30-years old, the 340B program is buckling under its own weight and overdue for reform. With legal action, including a Supreme Court ruling, …
The 30-year-old 340B drug discount program is due for reform Read More »
It’s no surprise the COVID-19 pandemic aggravated the United States’ already rampant opioid epidemic. But what’s more surprising, and devastating, has been the increase …
Teen opioid deaths are on the rise – but OTC Narcan could help Read More »
Could the Office of the U.S. Trade Representative’s (USTR) position on the COVID IP waiver be shifting? On December 6, USTR announced support for “extending …
Dobbs v. Jackson has had a ripple effect across healthcare—from increasing the danger of medical management of miscarriages and risk of maternal mortality, to …
How Dobbs v. Jackson is affecting vaccine innovation Read More »